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Abstract
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The rapid emergence of resistant bacterial strains has made the search for new antibacterial agents
an endeavor of paramount importance. Cationic antimicrobial peptides (AMPs) have the ability to
kill resistant pathogens while diminishing the development of resistance. Citropin 1.1 (Cit 1.1) is
an AMP effective against a broad range of pathogens. 20 analogues of Cit 1.1 were prepared to
understand how sequence variations lead to changes in structure and biological activity. Various
analogues exhibited an increased antimicrobial activity relative to Cit 1.1. The two most
promising, AMP-016 (W3F) and AMP-017 (W3F, D4R, K7R) presented a 2- to 8-fold increase in
activity against MRSA (both = 4 μg/mL). AMP-017 was active against E. coli (4 μg/mL), K.
pneumoniae (8 μg/mL), and A. baumannii (2 μg/mL). NMR studies indicated that Cit 1.1 and its
analogues form a head-to-tail helical dimer in a membrane environment, which differs from a prior
study by Sikorska et al. Active peptides displayed a greater tendency to form α-helices and to
dimerize when in contact with a negatively-charged membrane. Antimicrobial activity was
observed to correlate to the overall stability of the α-helix and to a positively charged N-terminus.
Biologically active AMPs were shown by SEM and flow cytometry to disrupt membranes in both
Gram-positive and Gram-negative bacteria through a proposed carpet mechanism. Notably, active
peptides exhibited typical serum stabilities and a good selectivity for bacterial cells over
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mammalian cells, which supports the potential use of Cit 1.1 analogues as a novel broad-spectrum
antibiotic for drug-resistant bacterial infections.

Keywords
Antimicrobial peptides; NMR structural biology; Peptide structures; Membrane disruption; Helical
peptides; Serum stability

1.

Introduction
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The emergence of drug resistant bacteria has made the development of novel antibacterial
agents a pressing issue [1]. In fact, most experts consider bacterial infections one of the
greatest threats to human health, which may result in more than 10 million deaths worldwide
by 2050 [2]. Bacterial resistance to common antibiotics occurs through a variety of
mechanisms [3]. For example, the Gram-positive pathogen methicillin resistant
Staphylococcus aureus (MRSA) copes with antibiotic agents by increasing its membrane
thickness or altering penicillin binding proteins (PBP) [4]. Gram-negative bacteria such as
Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
present resistance by virtue of a double membrane, by the development of efflux pumps, by
the production of degrading enzymes, by gene transfer or by altering drug binding targets
[5,6]. Antimicrobial peptides (AMPs) are an interesting option for combating resistant
bacteria to conventional small molecule antibiotics [7]. AMPs are capable of killing a wide
range of microorganisms by membrane pore formation, or membrane disruption. In addition,
AMPs can present antibacterial activity by inhibiting protein synthesis, enzymatic activity,
or cell wall synthesis [8–10]. The most attractive feature of AMPs is the observation that
bacteria are less likely to develop resistance to AMPs when compared to non-peptide
antibiotics [11]. This stems from the fact that the fundamental structure of the membrane is
not easily altered by mutations. In order to develop AMPs as antimicrobial agents it is
essential to determine its mechanism of action and the structural features that give rise to
their activities. This understanding is key to improving and evolving their efficacy.

Author Manuscript

Citropin 1.1 (Cit 1.1/AMP-001) is an AMP derived from the skin of an Australian tree frog
of the Litora genus. Cit 1.1 has shown intriguing activity against Gram-positive and Gramnegative species including: Staphylococcus aureus, Staphylococcus epidermis, Enterococcus
faecalis, Escherichia coli, and Klebsiella pneumonia [12]. Conversely, studies evaluated the
antifungical activity of Cit 1.1 against Candida species using direct bioautography [13] and
against Candida albicans, Candida tropicalis and Candida krusei isolated from patients with
oral cavity and respiratory tract infections [14]. They found that the peptide was weekly
active and less potent than amphotericin B and nystatin against clinical strains [13,14]. To
our acknowledge, Cit 1.1 has not been further tested against any other fungal strains besides
Candida ssp., suggesting the antifungal potential of this peptide and its analogues can be
further explored.
Previous structure-activity relationship (SAR) reports indicated that truncation of Cit 1.1
sequence, such as deletion of Gly1, Leu2, or Phe3, completely ablated the peptide’s activity.
On the other hand, deletion of Gly14, Gly15, or Leu16 had no impact on Cit 1.1 activity
Peptides. Author manuscript; available in PMC 2020 April 16.

de Almeida et al.

Page 3

Author Manuscript

[15]. Tyler and co-workers suggested that the α-helical conformation of Cit 1.1 was critical
to antimicrobial activity [16]. In fact, replacement of the L-amino acids with their D-isomers
yielded an AMP with similar biological activity [16]. Later studies showed that if an isoAsp
bond is formed between Leu5 and the carboxylic acid side chain of Asp4 biological activity
is abolished while the serum stability is greatly enhanced [17]. This conformational change
does not affect the total charge of Cit 1.1 and only marginally changes the isoelectric point
and hydrophobicity; however, an isoAsp bond significantly alters its secondary structure
hinting to the importance of the peptide’s conformation [17]. It has been additionally
proposed that two α-helices are formed upon contact of Cit 1.1 with bacterial membranes
[15]. Accordingly, an α-helical structure for Cit 1.1 appears to play an important role in the
peptide’s antimicrobial activity. It is important to note that these prior studies relied on the
introduction of relatively large structural changes to investigate a relationship between
amino acid composition and peptide conformation on biological activity.
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In this report, we sought to develop new Cit 1.1 analogues enhanced antimicrobial action
against various pathogens. Further, we expanded upon the previous structural investigations
by further characterizing the conformation and interactions of Cit 1.1 and its analogues in a
membrane mimetic environment. The membrane-bound solution structures of the Cit 1.1
peptides were determined using nuclear magnetic resonance (NMR) spectroscopy. The mode
of membrane disruption was visualized using transmission and scanning electron
microscopy techniques (TEM and SEM), flow cytometry and confocal microscopy. The
toxicity of the most potent AMP was studied in vitro against mammalian and human red
blood cells. Poor serum stability of peptide-based antimicrobials is another factor limiting
the use of AMPs and, therefore, we have also studied the serum stability of Cit 1.1 and its
analogs. The experimental data has enabled us to define a mechanism of action for Cit 1.1,
to describe the structural arrangement of the peptide when in contact with membranes, and
to understand the impact of subtle molecular and conformational changes on peptide
activity.

2.
2.1.

Results
Minimum inhibitory concentration (MIC assay)
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Cit 1.1 analogues were prepared using solid phase peptide synthesis (SPPS). Table 1 shows
the amino acid sequence of the synthesized peptides and the observed MIC values against S.
aureus JE2 (MRSA) and E. coli K12 (see Experimental S5 for detailed procedures). Cit 1.1
(AMP-001) displayed activity against MRSA (32 μg/mL) and E. coli (32 μg/mL)
corroborating findings from previous studies (Table 1) [16,18,19]. Cit 1.1, however, did not
demonstrate any activity against Acinetobacter baumannii, Candida albicans or
Cryptococcus neoformans (Table 2). AMP-002 with a methyl glycine (sarcosine, Sar1)
substituent retained activity against S. aureus (32 μg/mL) but exhibited diminished activity
against E. coli (64 μg/mL). The acetylation (AMP-003), the methylation to yield the
quaternary ammonium analogue (AMP-004), or substitution by a hydrazine group
(AMP-005) at the N-termini of Cit 1.1 eliminated antibacterial activity (MIC ≥ 256 μg/mL).

Peptides. Author manuscript; available in PMC 2020 April 16.
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Replacing the Lys residues (Lys7, Lys8) with ornithine (Orn), 2,4-diaminobutyric acid
(Dab), or 2,3-diaminopropionic acid (Dpr) yielded analogues AMP-006, AMP-007 and
AMP-008, respectively. These changes diminished the potency against Gram-positive
pathogen when compared to Cit 1.1 (Table 1). The peptides displayed equal (AMP-006 and
AMP-007, 32 μg/mL) or reduced antibacterial action (AMP-008, > 32 μg/mL) against
Gram-negative bacteria. On the AMP-009 analogue Lys7 was replaced with citrulline,
which substitution resulted in a lack of antibacterial activity. AMP-010 was synthesized by
methylating all of the available Cit 1.1 amine groups, whereas AMP-011 was generated by
methylating the Lys amine moieties to produce analogues with a resident positive charge.
Both AMP-010 and AMP-011 exhibited a complete lack of antibacterial activity. AMP-012
was constructed by replacing Lys7 and Lys8 with arginine residues, while the AMP-013
analogue was prepared by only substituting Lys7 for an arginine. The MICs for both
AMP-012 and AMP-013 decreased 2-fold against the MRSA strains (16 μg/mL) while the
activity against Gram-negative organisms was retained or diminished (MIC > 32 μg/mL)
when compared to Cit 1.1 (Table 1 and 2). Interestingly, AMP-012 and AMP-013 exhibited
antifungal activity with a MIC of 16 μg/mL against C. neoformans while AMP-012
displayed MIC of 16 μg/mL against Candida albicans (Table 2). A glycine residue was then
inserted following Lys 8, in order to alter the relative position of potentially key α-helical
residues. AMP-014 was observed to be inactive against the tested bacterial strains. The
AMP-015 analogue was designed with a modest substitution of Asp4 for Glu. Surprisingly,
AMP-015 was inactive against all bacterial strains tested (MIC > 32 μg/mL) but inhibited
the growth of C. neoformans with a MIC of 16 μg/mL.

Author Manuscript
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The AMP-016 analogue was constructed by replacing Phe3 with Trp, which yielded an
AMP with improved antibacterial activity against MRSA with MIC values of 8 μg/mL and 4
μg/mL for S aureus JE2 and S aureus ATCC 43300, respectively. AMP-016 also exhibited a
better antibacterial activity against E. coli K12 with an MIC value of 16 μg/mL. AMP-016
did not demonstrate antibacterial activity against K. pneumoniae or P. aeruginosa, but it was
active against A. baumannii (16 μg/mL), C. albicans (32 μg/mL) and C. neoformans (8 μg/
mL). The Asp4 and Lys7 residues where changed to Arg in the AMP-017 analogue,
producing the most potent analogue of the series which was effective against MRSA and E.
coli (MIC 4 μg/mL), K. pneumoniae (MIC 8 μg/mL) A. baumannii (MIC 2 μg/mL).
AMP-017 was also active against fungi with a MIC of 2 μg/mL against C. neoformans.
Replacement of Gly1 with PhenylGly (AMP-018), Phe3 with a biphenylalanine residue
(AMP-019), or 1-Naphyl (AMP-020) resulted in AMPs with improved antimicrobial
activity against bacteria and fungi, when compared with the lead compound. For example,
the MIC against MRSA was between 4–8 μg/mL. AMP-019 and AMP-020 were also active
against the dangerous A. baumannii with MIC = 16 μg/mL. Gly1 was replaced with Sar to
yield the AMP-021 analog, which presented promising MIC values against MRSA (8 μg/
mL), E. coli (16 μg/mL), A. baumannii (4 μg/mL) and C. neoformans (16 μg/mL).

Author Manuscript

2.2.

NMR spectroscopy
Negatively charged sodium dodecyl sulfate (SDS) micelles, which mimics the charge of
Gram-positive bacterial membranes, were therefore chosen as a model for the structural
elucidation of Cit 1.1, AMP-003, and AMP-016 peptides by NMR [20]. Standard twoPeptides. Author manuscript; available in PMC 2020 April 16.
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dimensional (2D) TOCSY and NOESY datasets were collected for backbone and side-chain
resonance assignments [21]. NMR assignments for Cit 1.1, AMP-003, and AMP-016 were
nearly complete with 94% HN, 100% Hα, 100% Hβ, 88% Hγ, 90–100% Hδ, 60–100% Hε,
0–33% Hζ, and 100% Hη of the assignments made (Table S7). Fig. 1A shows the Hα
chemical shift deviations from statistical-coil values for the three peptides bound to SDS
micelles [22,23]. The three peptides showed negative chemical shift differences across the
entirety of the sequence, which is strongly suggestive of an α-helical conformation along the
SDS micelle. Chemical shift differences between the Cit 1.1, AMP-003, and AMP-016
peptides were more apparent when HN chemical shifts were included. This is illustrated by
an overlay of the Hα region of the 2D TOCSY spectra for the three peptides as shown in
(Fig. 1B). Major chemical shifts changes were observed for residues 3 to 7, which are
consistent with the Hα chemical shift changes plotted in Fig. 1A. In order to reinforce this
observation, we performed circular dichroism (CD) studies. It was found the AMPs,
presented α-helical character (with some random coils) in aqueous media (Fig. S6). The
secondary structure of AMP-016 was also studied after 1 h incubation with E. coli and the
data showed the conformation was retained upon interaction with the bacteria membrane
(Fig. S7).

Author Manuscript

The NMR structures for the Cit 1.1, AMP-003, and AMP-016 peptides in SDS micelles
were determined to further elucidate the role that structure plays in antimicrobial activity.
The structural statistics for the three peptides (Table S8) indicates that the experimental data
agrees well with the calculated structures. Backbone RMSDs for each of the peptides was
0.3 Å, 0.7 Å, and 0.4 Å for Cit 1.1, AMP-003, and AMP-016, respectively. The structures
did not contain any NOE violations > 0.5 Å or dihedral angle violations > 5°. The high
quality of the NMR structures is also evident by the PROCHECK z-scores of −0.3, −0.95,
and −0.47 for Cit 1.1, AMP-003, and AMP-016, respectively [24]. Further, 92–94% of all
residues are located in the most favored region of the Ramachandran plot. An overlay of the
water refined 20 lowest energy NMR structures for the Cit 1.1, AMP-003, and AMP-016
peptides are shown in Fig. 2A–C.

Author Manuscript

The resulting NMR structures indicate that the Cit 1.1, AMP-003, and AMP-016 peptides
adopt a head to tail helical dimer (Fig. 2D–F). The head to tail orientation of the peptides
was confirmed by the presence of NOEs from Leu2 of strand A to Ile13/Leu16 of strand B.
These long-range structural restraints are only possible for a head to tail dimer. Of particular
note, a significant number of NOEs exist at the N-terminus (Fig. 2G, H), which is consistent
with the presence of both an α- and 310-helix for the biologically active peptides (Cit 1.1
and AMP-016). It is possible that the peptides adopt both conformations (or are in
equilibrium) when bound to a SDS micelle. In this case, the NMR structure would simply
represent an overall average of the conformational exchange. Importantly, the inactive
AMP-003 lacks a similar NOE pattern (and number of NOEs) at the N-terminus and, thus, it
exclusively adopts an α-helical structure (Fig. 2I). Since the only difference between Cit 1.1
and AMP-003 is the N-terminal acetylation, this clear difference in helix composition
between the peptides is due to the acetylation.
Amide proton temperature titrations up to 70 °C were performed on the three peptides to
characterize helical stability (Figs. S9–11). The titration data was binned according to the
Peptides. Author manuscript; available in PMC 2020 April 16.
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relative magnitude of the HN chemical shift changes (ΔHN): minor (0 to −0.05, yellow),
intermediate (−0.05 to −0.25, orange), and major (−0.25 to −0.45, red). The peptide ribbon
diagrams in Fig. 2D–F are colored based on these HN chemical shift changes in order to
qualitatively assess the thermal stability of the helices. Amino acid residues exhibiting major
chemical shift changes upon heating are transitioning from a stable and structurally-ordered
state to a disordered and unstructured state. Conversely, residues with relatively unchanged
chemical shifts are likely already in a transiently disordered state at room temperature.

Author Manuscript

Next the peptides were titrated with gadolinium-diethylenetriamine pentaacetic acid (GdDTPA) and monitored by NMR to identify the solvent exposed residues while the peptide
was bound to SDS micelles (Figs. S12–14). The addition of a paramagnetic species will
reduce the NMR signal intensity for residues in contact with the solvent proportionally to
the amount of the added paramagnetic species. Upon the addition of Gd-DTPA, the majority
of the amino acids exhibited an approximate linear decrease in peak intensity regardless of
location in the dimer structure. This is most likely due to multiple binding sites for GdDTPA on each peptide, an aggregation of the peptides along the surfaces of the micelles, and
a dynamic association/dissociation of the dimer [25]. Leu2 in Cit 1.1 and AMP-016 was an
exception to this general observation. The NMR peak intensity for Leu2 increased, at first,
with the addition of Gd-DTPA. Of note, the peak intensity for Leu2 was relatively weak
compared to the other residues (Fig. 1B), which is suggestive of a high exchange rate and/or
a transiently disordered structure.
2.3.

Scanning electron microscopy (SEM)
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S. aureus JE2 and E. coli K12 cells were treated for 1 h with Cit 1.1 or AMP-016 at 2X
MIC values. As clearly evident from the SEM images, AMP treatment led to membrane
disruption accompanied by cytoplasmic leakage, deep holes and severe membrane
deformations (Fig. 3). These morphological changes indicate that the AMPs kill bacteria by
disrupting cell membranes, although the results do not exclude additional mechanisms of
action. Please note the SEM micrographs present some differences between S. aureus and E.
coli, which may suggest a different mechanism of action for AMP antimicrobial activity
between Gram-positive and Gram-negative organisms. In the case of S. aureus, holes and
cytoplasm release were observed. Conversely, membrane solubilization due to a mixed
peptide/phospholipid vesicle formation (budding) with subsequent membrane thinning
leading to only a small amount of cytoplasm release was observed for E. coli.
2.4.

Propidium iodide (PI) uptake and flow cytometry

Author Manuscript

A PI uptake assay was performed to confirm the ability of AMPs to disrupt bacterial cell
membranes. S. aureus JE2 and E. coli K12 cells were treated with Cit 1.1 or AMP-016 at
2X MIC values. The PI fluorescence intensity was measured relative to Polymyxin B (PMB)
as a reference. Cit 1.1 and AMP-016 showed high PI uptake relative to controls (Fig. 4),
further suggesting that bacterial cell death is associated with membrane damage, since PI
can only cross damaged cell membranes. The cell membrane disruption of S. aureus JE2 and
E. coli K12 was further evaluated with flow cytometry. Untreated (no AMPs) and treatment
with 70% EtOH were used as negative and positive controls, respectively (Experimental S15
and Fig. S16). After 1 h treatment with either Cit 1.1 or AMP-016 at 2X MIC values, S.
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aureus cells showed an increased uptake, when compared to control, of 9.4% or 12.5%,
respectively (Fig. S16). Similarly, E. coli cells treated with either Cit 1.1 or AMP-016
exhibited cell viability of 13.9% or 27.5%, respectively.
2.5.

In vitro serum stability
Serum stability was assessed by incubating the peptides in human serum for over two hours
followed by quantitation using LC-MS/MS. AMP-002 and −006 displayed the highest
serum stability. Approximately 60%–80% of the peptides remained in the serum after 2 h.
Cit 1.1, −012, −013, and −016 displayed similar stabilities with only 40–50% of the peptide
remaining in the serum after 2 h (Fig. 5).

2.6.

Cytotoxicity

Author Manuscript

The cytotoxicity of the active AMPs against human embryonic kidney cells (ATCC
CRL-1573) was performed using a resazurin test and the IC50 values were determined from
dose response curves. The hemolytic activity was determined against human red blood cells
and the HC50 values (concentration at 50% hemolysis) were calculated by curve fitting of
the inhibition values versus log(concentration). The IC50 and HC50 values are summarized
in Table 3. In general, the AMPs showed IC50 values between 6.8 and 30.9 μg/mL.
AMP-012, AMP-016 and AMP-017 were exceptions and displayed IC50 values higher than
32 μg/mL. In addition, most of the AMPs exhibited low hemolytic activity with HC50 values
greater than 32 μg/mL. AMP-006, AMP-015 and AMP-016 were exceptions and displayed
lower HC50 values corresponding to 18.2 μg/mL, 16.8 μg/mL and 26.7 μg/mL, respectively.

3.
Author Manuscript

3.1.

Discussion
Antimicrobial activity
We have rationally designed analogues of the AMP Cit 1.1 to understand the contribution of
sequence and structure to its antibacterial activity. The N-terminus of AMPs tend to be polar
or ionic, which is likely to play a key role in membrane interactions [11]. In the AMP-002
analogue Gly1 was replaced with a methyl glycine. This change should increase serum
stability [26] and the lipophilicty at the N-terminus. The compound exhibited comparable
activity to Cit 1.1 against S. aureus JE2, but was half as potent against E. coli K12, which
suggests multiple H-bond donors may be needed at the N-terminus of AMPs for full activity.
This is consistent with the results obtained with the AMP-003 analog, which is acetylated at
the N-terminus. Acetylation of amines alters the pKa (preventing protonation) and the
isoelectric point while also reducing the net charge of the peptide [27].

Author Manuscript

To further investigate the importance of the primary amine on Cit 1.1 activity, the Nterminus was converted into a quaternary amine (AMP-004). This was based on the notion
that resident positive charges aid antibacterial activity [28,29]. This modification was
expected to have two distinct impacts on Cit 1.1 because: (1) a permanent positive charge is
pH-independent, but cannot form a hydrogen bond; (2) the quaternary amine makes the
AMP more resistant to proteolysis, which increases its bioavailability [30]. Unexpectedly,
AMP-004 was observed to be inactive against S. aureus and E. coli, indicating that a
positive charge on the N-terminal amine is not enough to interact with bacterial membrane.

Peptides. Author manuscript; available in PMC 2020 April 16.
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This suggests a role of H-bonding; either an interaction within the peptide (as suggested by
others) or an association with the bacteria that is important for activity. Similarly, replacing
Gly1 with a hydrazine group resulted in the loss of antibacterial activity for AMP-005.
Hydrazines have a lower pKa (~8.3) than amines (~9.6), a value that should be further
lowered by the neighboring electron-withdrawing group [31,32]. As a result, the hydrazine
nitrogen may not protonated (note that the alkylated nitrogen is the most likely site of
protonation [33]) under the conditions of the MIC assay. Furthermore, it is possible that an
internal hydrogen bond may form between the hydrogen on the hydrazine and the amide
carbonyl. In addition to preventing a hydrogen bond with the bacterial membrane, this
internal hydrogen bond may also affect the overall peptide structure and alter its biological
activity. The inactive AMP-003, AMP-004 and AMP-005 analogues clearly emphasize the
importance of the N-terminus in AMP activity and the potential critical role that hydrogen
bond donors and acceptors play in the interaction with the bacterial membrane. It is
important to note that although our NMR data clearly established different NOE patterns at
the N-terminus between the active and inactive peptides, the presence of NOEs do not
necessarily confirm the presence or absence of a hydrogen bond. Therefore, the speculation
on intramolecular hydrogen bond formation in the AMPs and at the membrane interface is
primarily based upon the chemical structures of the N-terminal modifications.
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AMPs usually contain two or more cationic side chains such as Lys and Arg, allowing for a
potential electrostatic interaction with the bacterial membrane. Accordingly, several
modifications to Cit 1.1 were made to evaluate the role of these charged residues to
antibacterial activity. Lys7 and Lys8 were replaced with progressively shorter amine bearing
sidechains: Orn, Dab, and Dpr. This change was intended to diminish lipophilicty while
instructing us of the role of charge projection within the α-helix. Replacing with Orn
(AMP-006) resulted in diminished activity against MRSA JE2 while the inclusion of Dab
(AMP-007) and Dpr (AMP-008) abolished the antibacterial against most of the tested
pathogens. These findings suggest the longer side chain of Lys is necessary for membrane
interaction and the antibacterial activity of Cit 1.1. Another possibility is that there is an
optimal hydrophobic index as a decrease in — CH2 units, results in lower hydrophobicity as
seen by the LogP values (Table 1) of −4.49, −5.52, −5.64, and −3.60 for Orn, Dap, Dpr and
Cit 1.1. Nevertheless, a direct correlation between LogP values and antibacterial activities
was not observed across the series. Indicating antibacterial activities is dependent on a
combination of multiple factors.
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The Lys residues were methylated to explore the relative contribution of electrostatic
interactions and hydrogen bonds to biological activity. Unexpectedly, and despite having a
permanent +3 charge, both AMP-010 and AMP-011 were found to be inactive. This result
implies a H-bond donor is key to the biological activity of Cit 1.1 and its analogs.
Arginine-rich peptides have also been shown to exhibit potent antibacterial activity [34,35].
In fact, a number of studies have indicated that an increase in arginine versus lysine content
results in higher antimicrobial action [36,37]. To investigate this, a Cit 1.1 analogue
(AMP-012) was constructed where Lys7 and Lys8 were replaced with an arginine. An
AMP-013 analogue was also prepared that only replaced Lys7 with an arginine. The MICs
for both AMP-012 and AMP-013 decreased 2-fold against S. aureus to 16 μg/mL. The
Peptides. Author manuscript; available in PMC 2020 April 16.
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increase in antimicrobial activity may be explained by an enhanced translocation of peptides
within the S. aureus cells [38,39]. However, the AMP-012 and AMP-013 displayed
diminished activity against most of the Gram-negative organisms tested. Interestingly,
AMP-012 exhibited antifungal activity against both C. albicans and C. neoformans (16 μg/
mL). To further explore the importance of cationic residues on activity, citrulline a structural
mimic of arginine containing a urea functional group instead of the charged guanidium
group was constructed (AMP-009). This substitution resulted in a complete lack of
antibacterial activity, further establishing the importance of a charged H-bonding donor at
position 7 (the citrulline urea group is capable of forming a hydrogen bond but its side chain
is uncharged). The citrulline substitution reduces the net charge of AMP-009, which
suggests the net charge of the peptide also contributes to the antimicrobial activity of AMPs.
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Previous studies have shown that Cit 1.1 adopts an α-helical conformation, but there has
also been some conflicting evidence about the exact details of the Cit 1.1 structure [15].
Instead of a single α-helical chain, two helices have been suggested for the Cit 1.1 structure
[15]. To address this possibility, a glycine residue was inserted into the Cit 1.1 sequence
following Lys8 to create the AMP-014 analog. The insertion of Gly9 was expected to
provide added flexibility to the peptide [40,41] and potentially enhance its activity if the
two-helix model was correct. AMP-014 was observed to be inactive against all the bacterial
strains tested and suggests the two-helix model for Cit 1.1 may be incorrect. If the Cit 1.1
structure is comprised of two α-helices separated by a flexible link, then the inserted Gly
may allow enough mobility for the correct surface of the α-helices to interact with the
membrane. Nevertheless, it is important to note the Gly insertion lengthens the peptide and
shifts the sequence beyond Lys8 affecting the charge distribution at the Cit 1.1 surface.
Thus, the loss in activity may also be explained by a change in the position of the
hydrophobic and charged residues.
The AMP-015 analog, which contains a Glu for Asp4 substitution, was also inactive. Others
have suggested a potential H-bond between the N-terminus and residue 4 [16]. This change
may affect such interaction but no change in activity was observed. AMP-016 was
constructed by replacing Phe3 with Trp. Tryptophan-rich peptides have been shown to
enhance the activity of AMPs presumable due to a larger hydrophobic area [34,42] and the
insertion of Trp residues at the membrane-water interface [41]. The AMP-016 analogue
exhibited a 4-fold and 2-fold increase in activity against S. aureus and E. coli, respectively.
In addition, AMP-016 was active against C. neoformans (8 μg/mL). Thus, we think the
indole ring in tryptophan is likely acting as a better anchor to the bacterial membranes than
the smaller phenyl ring [42].
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AMP-017, AMP-018 and AMP-21 were designed to maintain the increased antimicrobial
activity resulting from the inclusion of Trp at position 3, while investigating the impact of
other amino acid substitutions at different positions. AMP-017 (Asp4 and Lys7 were
replaced by Arg) showed an increase in activity against E. coli, K. pneumoniae, A.
baumannii and C. neoformans when compared with Cit 1.1 or AMP-016. However,
replacing Gly1 with PhenylGly and Lys7 with Arg (AMP-018) dramacticaly decreased the
activity of AMP-017 against bacteria (still, this compound was better than Cit 1.1).
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AMP-021, where Gly1 was replaced by Sar and Lys7 by Arg, showed a slight decrease in
activity against Gram-negative strains that AMP-017. However, the molecule had better
activity than Cit 1.1 or AMP-018. This results indicate the key role of Trp3 or Arg4 on
activity.
We also replaced Phe3 with other aromatic amino acids; biphenylalanine or naphthylalanine
(AMP-019 and AMP-020). These replacements maintained the activity observed with
AMP-016 against S. aureus, while reducing activity against Gram-negative bacteria and
fungi. The analogue was slighlty more potent than Cit 1.1. These finding may also be
correlated to the increasing hydrophobicity (LogP −1.85, −2.61, and −3.60 for AMP-019,
AMP-020 and Cit 1.1, respctively) which may facilitate the peptide insertion into the
bacteria membrane. Fig. 6 summarizes the structure-activity relationship for the series of
AMP analogs.

Author Manuscript

3.2.

NMR spectroscopy

Author Manuscript

Cit 1.1, AMP-003, and −016 were analyzed by NMR to elucidate the relationship between
structure and antimicrobial activity. Interestingly, Fig. 1A indicates that the largest Ha
chemical shift difference between the three peptides occurs at the N-terminus between
residues Asp3 and Lys7. Although the dissimilarity between AMP-016 and Cit 1.1/
AMP-003 can be attributed to the tryptophan substitution at position 3, the minor deviation
of Asp4 is likely a result of the acetylation of the N-terminus. In the case of AMP-016, the
steric and electronic effects from the indole side chain at position 3 may lead to a significant
decrease in helicity. N-terminal acetylation does not induce any significant effect on the
overall helicity of AMP-003 except for a slight decrease at Asp4. The removal of the
charged N-terminus changes the polarity or the hydrogen-bond network around Asp4, which
contributes to a decrease in helicity. Fig. 1B shows the overlay of the Hα region of the 2D
TOCSY for the three peptides. The significant chemical shift differences of the N-terminal
residues highlight a changing local environment for residues 3 to 7 that is likely a result of
minor alterations in the structure of the three peptides. Accordingly, these subtle changes in
the peptide’s structure may be directly related to differences in antimicrobial activity.

Author Manuscript

Our NMR derived structures for Cit 1.1, AMP-003, and −016 differ from the previous
results of Sikorska et al. that describe the presence of two helices within Cit 1.1 structure
[15]. Experimentally determined NOEs were found along the full length of each of the
peptides (Fig. 2G–I) and between the helices in a dimer orientation. Although the Cit 1.1,
AMP-003, and AMP-016 dimers are not completely superimposable, there are no major
structural differences between the three peptide structures that appear to explain the
difference in activity. In all cases, the dimers pack together along a hydrophobic face, which
then exposes charged residues to the solvent. Consequently, the peptides’ NMR structures
are consistent with the prior observation that the number and distribution of hydrophobic
residues is crucial for antimicrobial activity [43]. Increasing peptide hydrophobicity
increases antimicrobial activity, but only if the overall hydrophobicity remains below an
optimal upper threshold. Peptide aggregation likely occurs if too many hydrophobic residues
are inserted into the peptide sequence, which leads to a loss in activity. Therefore, the Cit
1.1 peptide must maintain a hydrophobic surface to allow for a stable dimer in order to
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carpet a bacterial cell membrane, but must also avoid the formation of inactive aggregates.
The tryptophan substitution in AMP-016 and the corresponding increase in antimicrobial
activity supports the above hypothesis. The hydrophobic and electrostatic properties of
tryptophan [44] allows AMP-016 to maintain a similar overall hydrophobicity to Cit 1.1
while also promoting peptide aggregation at the membrane surface, and a positive
electrostatic interaction with the negatively-charged membrane. This, however, does not
explain the differences in activity between the active (Cit 1.1/AMP-016) and inactive
(AMP-003) peptides since all of the peptides form a similar head-to-tail dimer. Instead, the
primary difference between the active and inactive peptide dimers is the N-terminal
acetylation.

Author Manuscript
Author Manuscript

It has been previously observed that N-terminal acetylation increases the propensity of αhelix formation in peptides regardless of the amino acid sequence [45]. N-terminal
acetylation also increases the overall stability of an α-helix. In the case of Cit 1.1, the
apparent increase in helical stability due to acetylation resulted in a loss of activity.
Consequently, antimicrobial activity may be correlated with a certain amount of structural
disorder or mobility within the peptide. Of course, this result can also be linked to the loss of
basicity as explained earlier. The NMR also leads to the theory that antimicrobial activity
may depend on an equilibrium between a disordered monomer in solution and helical dimers
coating the membrane surface. In the presence of bacteria, the equilibrium shifts from
disordered monomer to the helical dimer. The dimer is then able to associate with other
dimers on the membrane surface and promote antimicrobial activity through a proposed
carpet mechanism. However, if the peptide is stabilized in solution then the equilibrium is
shifted away from interacting with the bacterial membrane and the antimicrobial activity is
abolished. We hypothesize that Cit 1.1 exists as a disordered monomer in solution and
dimerizes and aggregates along the anionic surface of the bacterial membrane. In the
inactive form, the N-terminal acetylation stabilizes the transiently formed α-helix in
solution. Consequently, the aggregation on the membrane surface, which promotes
antimicrobial activity, is greatly diminished. Again, the observation that the inactive
AMP-003 dimer is exclusively α-helical and the Cit 1.1/AMP-016 dimers are a mixture of
α- and 310-helix is supportive of the proposal that helix stability affects antimicrobial
activity. To further investigate the role of α-helical stability in regard to antimicrobial
activity, NMR was used to measure the thermal stability and solvent accessibility of the Cit
1.1, AMP-003, and AMP-016 peptides.

Author Manuscript

The temperature-dependent chemical shift changes clearly define the dimer interface as the
residues with the largest ΔHN values (Figs. 2D–F, S1–3). The residues in the dimer interface
correspond to: Ile6, Val9, Ala10, Ile13, and Gly14. Importantly, the inactive AMP-003
peptide exhibited the smallest HN chemical shift changes for these residues. This suggests
the inactive AMP-003 is relatively less stable as a dimer in the SDS micelle compared to the
active peptides. Interestingly, there are additional AMP-003 residues outside of the dimer
interface that also exhibit a temperature-dependent chemical shift change. This was not
observed for the Cit 1.1 or AMP-016 peptides. One possible explanation for this difference
is that the AMP-003 peptide still maintains an α-helical structure as a monomer, which
undergoes further temperature-dependent denaturation. This does not appear to occur for Cit
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1.1 or AMP-016. In fact, more residues in the Cit 1.1 peptide compared to AMP-003 are
disordered based on the lack of a temperature-dependent chemical shift change. These
results suggest that a certain amount of structural disorder or dynamics is necessary for
antimicrobial activity.
The presence of a helical dimer is also suggested by the Gd-DTPA titration experiments. At
low concentrations of Gd-DTPA, the amide peak intensity for Leu2 was found to increase,
which indicates a reduction in the chemical exchange with the solvent. It is plausible that the
coordination of Gd-DTPA by the active peptides stabilizes the dimer structure and reduces
the amide chemical exchange of Leu2 causing an initial sharpening of the peak. Only at
higher Gd-DTPA concentrations does the Leu2 NMR resonance broaden like the other
amino acid residues. This effect is not seen in the inactive peptide (AMP-003), suggestive of
a more stable α-helix along the entirety of the peptide monomer (Fig. S4–6).

Author Manuscript

3.3.

Mechanism of action in bacteria membrane

Author Manuscript

Bacterial membrane disruption can be described by the worm-hole, the barrel-stave, or the
carpet models [46,47]. Previously reported data on the Cit 1.1 interaction with negatively
charged lipid vesicles hinted towards involvement of the carpet mechanism [12]. In the
carpet-model of membrane disruption, the AMPs bind parallel to the bacterial membrane
covering its entire surface. This causes cell membrane permeation and eventually release of
small vesicles from the membrane [46,47]. A separate study involving giant unilamellar
vesicles (GUVs) further supported the carpet mechanism proposed earlier [40]. Conversely,
an atomic force microscopy study by Henderson and colleagues indicates that Cit 1.1 can
promote the formation of worm-like micelles, which could be an outcome of many toroidal
pore formations [48]. However, those prior studies relied on negatively charged phospholipid
model membranes, which are structurally simple compared to bacterial membranes. These
model membranes do not accurately represent the complexity of single or doublemembraned Gram-negative organisms. Furthermore, those studies relied on indirect
fluorometric observations instead of direct microscopic imaging [12,46]. Treatment of S.
aureus and E. coli with AMP-016 lead to membrane disruption accompanied by the
formation of protruding blebs and holes as visualized by SEM (Figs. 3) and transmission
electron microscopy (not shown). The carpet mechanism of membrane disruption is
commonly associated with detergent-like antibacterials displaying indiscriminate cell lytic
properties and AMPs acting by this mechanism may possess some basic structural
requirements [8]. Herein, we have shown that AMPs that disrupt membranes in a detergent
like fashion are sensitive to subtle structural modifications. Additionally, the membrane
damage in MRSA JE2 and E coli K12 was also confirmed by a PI uptake assay and by flow
cytometry experiments, showing an increase in the fluorescent intensity of PI after treatment
with AMP-016.

Author Manuscript

3.4.

In vitro serum stability studies
AMPs have found limited use due to their susceptibility to metabolic enzymes in serum and
the liver. Accordingly, some of the Cit 1.1 analogues were tested for serum stability.
AMP-002 was the most serum-stable peptide of the tested AMPs with about 80% of the
peptide remaining after 2 h. of incubation. This was expected because peptides can be
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degraded starting from the N-terminus by exopeptidases [49]. Thus, an alkylated N-terminus
may be a successful strategy for enhancing AMP stability [30], which may explain the twofold increase in serum half-life for AMP-002 compared to Cit 1.1. AMP-006 was also more
stable in serum compared to Cit 1.1, with approximately 60% of the peptide remaining after
a 2-hr. incubation in serum. AMP-006 had Lys7 and Lys8 substituted by Orn residues. The
presence of this unnatural amino acid may prevent recognition by LysC and LysN
endopeptidases [50]. N-terminus modification and substitution with unnatural amino acids
may enhance AMP plasma stability and bioavailability [51], but retaining bioactivity is still
paramount. The data suggests alkylation of the N-terminus is an interesting strategy to
enhance the stability of Cit 1.1 analogues.
3.5.

Cytotoxicity

Author Manuscript

For therapeutic use, AMPs should display good selectivity for bacterial cells over
mammalian cells. The active peptides, AMP-016 and AMP-017 showed both IC50 and HC50
values higher than their MICs and displayed minimal hemolytic activity against human red
blood cells. We theorized that AMPs should possess a greater affinity for negatively charged
bacterial membranes compared to zwitterionic mammalian cell membranes. In fact, prior
studies have suggested that AMPs exhibit a higher affinity to bacteria compared to
mammalian cells because of their distinct membrane characteristics [7,47,52]. For example,
the transmembrane potential is more negative in bacteria cells, which suggest an increase
affinity or sensitivity of bacteria cells for cationic antimicrobial peptides [7].

4.

Conclusion

Author Manuscript
Author Manuscript

We have shown that AMP-membrane interactions impact antimicrobial activity. Rationally
designed Cit 1.1 analogues were used to develop SAR and to elucidate previously unknown
interactions responsible for membrane disruption and antibacterial activity. Our insights
regarding Cit 1.1 structural features essential for activity are summarized in Fig. 6.
Hydrogen bond donors with a basic pKa at the N-terminus were found to be indispensable
for antibacterial activity. Ablation of either the hydrogen bond donors or the positive charge
resulted in inactivity; suggesting a complementary effect between hydrogen bonding and
electrostatic interactions in disrupting membranes. Also, sufficient projections of the side
chain amine groups were shown to be essential for membrane disruption. AMP-016 and
AMP-017 are highly potent Cit 1.1 analogues with a 2- to 8-fold increase in antimicrobial
activity against MRSA. Both analogues have a Trp residue that replaces the native Phe.
Thus, the improved activity may be due to an increase in the bulk of the hydrophobic anchor
and an improved electrostatic interaction with the negatively-charged membrane. The W3F
modification also made Cit 1.1 analogues active against fungi. NMR studies revealed the
propensity of AMPs to form head-to-tail helical-dimers on the surface of anionic membranes
and bacterial surfaces. NMR spectroscopy exposed a positive correlation between AMP
helicity and antibacterial activity, where N-terminal acetylation increased the α-helical
structure of the peptides in the absence of a membrane and, correspondingly, lead to a
decrease in antibacterial activity. These experiments provide further support for the carpet
model of membrane disruption, which was subsequently confirmed by electron microscopy
in both Gram-positive and Gram-negative bacteria. The results presented herein provide the
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critical foundation for further evolving Cit 1.1 analogues into novel broad-spectrum
antibiotics for the treatment of drug-resistant bacterial infections.

5.
5.1.

Experimental section
Peptide synthesis and purification

Author Manuscript

AMPs were synthesized using solid phase peptide synthesis (SPPS) on a Focus XC
automated peptide synthesizer (AAPPTec, Louisville, KY) on a 0.25 mmol scale. All
peptides were synthesized using Fmoc-Rink Amide AM resin support (AAPPTec,
Louisville, KY). The resin was wetted in dichloromechane (DCM) for 30 min. to promote
swelling. The Fmoc- group was then deprotected twice using 20% 4-methyl piperidine in
dimethyl formamide (DMF) (10 mL). The resin was thoroughly washed twice for 10 min.
using a 15 mL 1:1 mixture of DCM and DMF. The desired amino acids were then added to
obtain a predetermined sequence in the peptide synthesizer. Molecular weight of the AMPs
was confirmed by MALDI using a 4800 MALDI TOF/TOF analyzer (SCIEX, Ontario,
Canada). The AMPs were purified using a preparative high-performance liquid
chromatography (HPLC) using a water (0.1% trifluoroacetic acid (TFA)) and acetonitrile
(0.1% TFA) gradient on an HPLC system (Agilent, Santa Clara, CA) with a reverse phase
column (Kinetex5 u XB-C18 100 A, 150 × 30.0 mm column). Each AMP was confirmed to
be > 95% pure. The relative hydrophobicity of the AMPs was determined by simultaneously
measuring retention times with the analytical HPLC system described above.
Special peptide modifications were done on resin and described as follows:
AMP-002 was synthesized by coupling a Sar instead of glycine following the procedure
described above.

Author Manuscript

AMP-003 was acetylated by shaking the complete peptide loaded resin in 1 mL acetic
anhydride dissolved in 5 mL (DCM:DMF = 1:1) for 6 h at ambient temperature.
AMP-004 was synthesized by methylating the Fmoc-deprotected N-terminus by adding 4
mL methyl iodide and 200 μL triethylamine to the resin in 10 mL DCM and then gently
heating at 45 °C for 5 days.
AMP-005 was synthesized by substituting the glycine residue with bromoacetic acid using
the same coupling procedure as described above. The bromine was then displaced with 10
mL hydrazine hydrate by reacting it on the resin for 24 h.

Author Manuscript

AMP-010 was synthesized by first making GLFDVIK(Alloc)K (Alloc)VASVIGGL on the
resin. The N-terminus Fmoc was deprotected following the procedure described above. The
side chain Alloc was deprotected on resin by treatment with 0.35 eq of Pd(PPh3)4 and 20 eq
of Phenyl silane in DCM for 45 min. Methylation of the free primary amines was achieved
by adding 4 mL methyl iodide and 200 μL triethylamine to the resin in 10 mL DCM and
then gently heating at 45 °C for 5 days.
AMP-011 was synthesized by first making Fmoc-GLFDVIK(Alloc)K (Alloc)VASVIGGL
on the resin. The side chain Alloc was deprotected on the resin by treatment with 0.35 eq
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Pd(PPh3)4 and 20 eq Phenyl silane in 10 mL DCM for 45 min. Methylation of the free
primary amines were achieved by adding 4 mL methyl iodide and 200 μL triethylamine to
the resin in 10 mL DCM and then gently heating at 45 °C for 5 days. Finally, the Fmocgroup was deprotected following the procedure described above.
5.2.

Minimum inhibitory concentration assay (MIC)

Author Manuscript

MICs for Cit 1.1 and the Cit 1.1 analogues were measured using the following bacterial
strains: S. aureus JE2 and E. coli K12. The MICs was determined using the broth
microdilution method as previously described [52]. A stock solution of each peptide was
prepared in milliQ water and then serial 2-fold dilutions were made in Difco™ Muller
Hinton Broth (MHB) (BD Diagnostics, Becton Drive, NJ) in Cellstar 96-well microtiter
plates (Greiner Bio-One, Kremsmünster, Austria). Bacterial cultures were prepared using the
direct colony suspension method to 1.5 × 108 colony forming unit (CFU)/mL (0.5
McFarland) and diluted from 2 mL into 40 mL of MHB. Each well was inoculated with 10
μL of bacterial cultures. Plates were statically incubated at 37 °C for 24 h. MIC values
correspond to the lowest AMP concentration that yielded no observable bacterial growth
based on analysis with the unaided eye or a microplate reader. The optical density (O.D.)
value at 600 nm was recorded using an AccuSkan, MultiSkan FC (Thermo Fisher, Waltham,
MA). Vancomycin (Sigma, St. Louis, MO) and gentamicin (Alfa Aesar, Ward Hill, MA)
were used as positive controls. Blank media was used as a negative control. All assays were
performed in triplicates using three independent measurements. All assays were performed
in triplicates using three independent measurements.
5.3.

NMR structure determination

Author Manuscript
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Unlabeled Cit 1.1 and the Cit 1.1 analogues samples were prepared similarly to previous
studies [15]. Briefly, 2mM of Cit 1.1, AMP-003, or AMP-016 were dissolved in 90% H2O
and 10% D2O with 120 mM of SDS-d25 (Cambridge Isotope, Ewksbury, MA), 50 mM
trimethylsilylpropanoic acid (TMSP), and PBS buffer at pH 7 (uncorrected). NMR
experiments were collected at 25 °C on a 700 MHz Avance III spectrometer (Bruker,
Billerica, MA) equipped with a 5 mm QCI-P probe with cryogenically cooled carbon and
proton channels. 1H chemical shift and NOE assignments were accomplished with TOCSY,
DQF-COSY, and NOESY experiments with chemical shifts referenced to TMSP. NMR
spectra were collected with 32 transients and 512 points in the indirect dimension. NOESY
spectra were collected with mixing times of 100 ms and 200 ms. Inter-strand NOEs were
identified using a 3D X-filtered experiment with a mixing time of 120 ms and a 50/50
mixture of unlabeled peptide and a peptide uniformly 13C, 15N labeled at Leu2 [53]. Initial
models of the AMPs were generated from Hα chemical shifts using the CS-Rosetta
webserver at the BMRB [54]. Structural refinement was carried out with XPLOR-NIH with
dimer symmetry enforced [55]. The three AMP dimer structures were determined with 536
to 622 intramolecular NOE restraints, and 16 intermolecular (peptide-peptide) NOE
restraints. A total of 400 models were calculated per AMP and the lowest 20 energy
structures were subsequently subjected to water refinement in XPLOR-NIH. Validation of
the AMP ensembles was done using the Protein Structure Validation Software (PSVS, http://
psvs-1_5-dev.nesg.org/) suite from the Northeast Structural Genomics Consortium (NESG)
[56].
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The unlabeled NMR Cit 1.1, AMP-003, or AMP-016 samples used for structure
determination were also subjected to a temperature titration to monitor structure stability. 1D
1H NMR spectra were recorded at temperatures of 25, 30, 40, 50, 60, and 70 °C with 64
transients, 131k data points, and a spectral width of 12.87 ppm. Between each experiment,
the samples were allowed to rest at the target temperature for 5 min before data collection.
Following the titration, the 25 °C spectrum was recollected to ensure that the sample did not
undergo irreversible degradation upon heating.
5.5.

Paramagnetic relaxation enhancement titration
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The unlabeled NMR Cit 1.1, AMP-003, or AMP-016 samples used for structure
determination were also used to observe the effects of a diethylenetriaminepentaacetic acid
gadolinium (III) dihydrogen salt hydrate (Gd-DTPA) titration. Gd-DTPA was titrated into
the samples to concentrations of 0, 2, 4, 8, 16, and 24 mM. 1D 1H NMR spectra were
recorded with 128 transients, 64k data points, and a spectral width of 12.87 ppm. Effects
resulting from sample dilution were accounted for by normalizing peak intensities to TMSP.
5.6.

Scanning electron microscopy (SEM)
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E. coli K12 and S. aureus JE2 were cultured in MHB and incubated at 37 °C. The resultant
mid-log phase cultures were diluted to a final concentration of 1.5 × 108 CFU/ml (0.5
McFarland). The bacteria cells were treated with Cit 1.1 or a Cit 1.1 analogue at 2X the
MIC value and incubated for 1 h at 37 °C. A control was prepared by adding only media.
After AMP treatment, the cells were immediately washed thrice with HyClone™
Dulbecco’s PBS solution (GE Healthcare Life Science, Marlborough, MA) and fixed with
2.0% (v/v) glutaraldehyde [57]. The bacterial suspension was then placed on 0.1% Poly-L
Lysine coated glass slide and allowed to adhere for 30 min. The slides were washed thrice
with PBS to remove excess fixative. Samples were post-fixed in a 1% solution of OsO4 for
30 min. to facilitate conductivity. The samples were then dehydrated in a graded ethanol
series (50, 70, 90, 95, and 100%). Ethanol was removed by washing the slides thrice with
hexamethyldisilazane (HMDS). HMDS was allowed to evaporate overnight to dryness. The
glass slides were attached to aluminum SEM stubs with double-sided carbon tape. Silver
paste was applied to enhance conductivity, which was allowed to dry overnight. Samples
were then coated with approximately 50 nm gold-palladium alloy in a Hummer VI Sputter
Coater (Anatech, Battle Creek, MI) and imaged at 30 kV in a Quanta 200 SEM (FEI,
Hillsboro, OR) operating in high vacuum mode.
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5.7.

Propidium iodide (PI) uptake
The PI uptake assay was performed according to Shireen et al [58]. S. aureus JE2 and E. coli
K12 cells were grown in BHI broth to the mid logarithmic-phase and the bacterial cells were
harvested by centrifugation at 5000 rpm for 5 min and washed once with PBS buffer. Cells
were diluted to 107 cfu/ml using PBS buffer. AMPs were added to each well at twice the
MIC. Similarly, 10 μg/mL of PI was also added to each well. Polymyxin B was used as a
reference drug and cells with no AMP treatment were used as a control. PI fluorescence was
measured at 37 °C and at 20 min intervals for a total duration of 120 min. The PI
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fluorescence was measured using a spectrofluorometer with excitation and emission
wavelengths set at 544 nm and 620 nm, respectively.
5.8.

In vitro human serum stability studies
Cit 1.1 and Cit 1.1 analogues were incubated in human serum for 2 h in a shaking water
bath (90 rpm) at 37 °C. Peptide content in the reaction mixture was below 0.5% (v/v). At
select time intervals of 0, 30, 45, 60 and 120 min, 100 μL of the serum-AMP mixture was
extracted and quenched with 400 μL of methanol containing oxibendazole as an internal
standard. Samples were mixed and centrifuged at 17,950 × g for 15 min. at 4 °C. 100 μL of
the supernatant was removed for analysis. Stability results were expressed as a percentage of
AMP remaining in the serum as a function of time. AMP stability was represented as the
percentage of the AMP remaining relative to the first time-point (0 min; 100% AMP). All
experiments were performed in triplicate.
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A LabSolutions LCMS Ver.5.6 controlled UPLC and MS system consisting of a Shimadzu
LC-MS/MS 8060 equipped with a DUIS source, two pumps (LC-30 AD), a column oven
(CTO-30AS) and an auto-sampler (SIL-30AC) were used to quantitate AMPs in human
serum. The MS/MS system was operated at unit resolution in the multiple reaction
monitoring (MRM) mode using the precursor ion to product ion combinations of: (i) 538.92
to 86.20 m/z, (ii) 543.60–86.20 m/z, (iii) 557.60–86.25 m/z, (iv) 529.60–86.25 m/z, (v)
548.25 to143.20 m/z, and (vi) 551.95 to 86.20 m/z for Cit 1.1, AMP-002, AMP-006,
AMP-012, AMP-013 and AMP-016, respectively. All of the AMPs were triply charged (m
+ 3). Mass detection ocoored in the positive ionization mode with the following parameters:
nebulizer gas: 2.0 L/min; heating gas: 10 L/min; drying gas: 10 L/min; interface
temperature: 375 °C; desolvation line temperature: 250 °C; and heat block temperature: 400
°C.

Author Manuscript

Acceptable resolution and peak shape were achieved for the AMPs on a BEH C18 (1.7
μg/mL, 2.1 × 100 mm, Waters, Milford, MA) column protected with a C18 guard column
(Phenomenex, Torrance, CA). The mobile phase consisted of 0.1% formic acid in water
(mobile phase A) and methanol (MeOH) (mobile phase B) at total flow rate of 0.25 mL/min.
Chromatographic separation was achieved using an 8-minute gradient elution. The initial
mobile phase composition was 35% B, which was increased linearly to 95% B over 6 min.
The mobile phase was then held constant at 95% B for 1.0 min and returned to the initial
condition in 0.5 min followed by a 1 min equilibration. The sample injection volume was 5
μL. Calibration curves were established for each analyte using the peak area ratio
(analyte/IS) and known concentration. Each calibration curve consisted of a blank sample, a
zero blank (blank and IS), and eight non-zero concentrations. All analytes were extracted
from the respective matrix by simple protein precipitation extraction using methanol spiked
with the IS. The method was linear over the range from 1 to 1000 ng/mL for all analytes.
The acceptance criteria for each back calculated standard concentration was ± 15% standard
deviation (SD) from the nominal value except at LLOQ, which was set at ± 20%.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Peptides. Author manuscript; available in PMC 2020 April 16.

de Almeida et al.

Page 18

Author Manuscript

Acknowledgements
This work was funded by UNMC-startup funds (MC-S), National Institute of Health-NIGMS, Nebraska Center for
Molecular Target Discovery and Development (1P20GM121316-01A1, PI: Robert Lewis, Project Leader, MC-S),
and by the USA Department of Defense-Peer Reviewed Medical Research Program 2017 (W81XWH-18-1-0113,
MC-S). This work was supported by funding from the Redox Biology Center (P30 GM103335, NIGMS, RP) and
the Nebraska Center for Integrated Biomolecular Communication (P20 GM113126, NIGMS, RP). The research was
performed in facilities renovated with support from the N.I.H. (RR015468-01). Some antimicrobial tests (as
detailed in the SI) were performed by The Community for Antimicrobial Drug Discovery (CO-ADD), funded by
the Wellcome Trust (UK) and The University of Queensland (Australia). The authors thank Dr. Andrew Dudley,
Tom Bargar, and Nicholas Conoan (UNMC-Electron Microscopy Core Facility, EMCF) and Samantha Wall
(UNMC-Flow Cytometry Research Facility, FCRF) for technical assistance. The EMCF and FCRF are supported
by the Nebraska Research Initiative (NRI), the University of Nebraska Foundation, and the UNMC-Office of the
Vice Chancellor for Research. FCRF is also supported by The Fred and Pamela Buffett Cancer Center’s through the
NCI.

Abbreviations
Author Manuscript
Author Manuscript
Author Manuscript

ALLOC

allyloxycarbonyl

AMP(s)

antimicrobial peptide(s)

CFU

colony forming unit

Cit 1.1

Citropin 1.1

CLint

in vitro intrinsic clearance

Dab

2,4-diaminobutyric acid

DFQ-COSY

double quantum filtered COSY

Dpr

2,3-diaminopropionic acid

Fmoc

fluorenylmethyloxycarbonyl

Gd-DTPA

gadolinium-diethylenetriamine pentaacetic acid

HMDS

hexamethyldisilazane

IC50

half maximal inhibitory concentration

MIC

minimum inhibitory concentration

Orn

ornithine

PMDS

polydimethylsiloxane

PSVS

protein structure validation software

Sar

sarcosine

SEM

scanning electron microscopy

TMSP

trimethylsilylpropanoic acid

TOCSY

TOtal Correlated Spectroscopy
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(A) Plot showing the Hα deviations (ppm) from statistical-coil chemical shifts. Amino acids
are numbered according to their sequence in Cit 1.1 (red), AMP-003 (green), and AMP-016
(blue). (B) TOCSY Hα region for Cit 1.1 (red), AMP-003 (green), and AMP-016 (blue).
Peaks are labeled according to their respective amino acid position.
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The ensemble of the lowest energy, water refined structures of (A) Cit 1.1, (B) AMP-003,
and (C) AMP-016. Peptide ribbon structures for (D) Cit 1.1, (E) AMP-003, and (F)
AMP-016 are colored by the binned amide proton temperature titration data according to the
ΔH ranges 0 to −0.05 (minor chemical shift, yellow), −0.05 to −0.25 (intermediate chemical
shift, orange), and −0.25 to −0.45 (major chemical shift, red). NOE connectivity plots for
(G) Cit 1.1, (H) AMP-003, and (I) AMP-016. Weights of the connectivities are normalized
to the NOE intensities.
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Fig. 3.

SEM micrographs of S. aureus JE2 MRSA (top row) and E. coli K12 (bottom row) cells
treated with either Cit 1.1 or AMP-016 at twice the MIC reported in Table 2.

Author Manuscript
Author Manuscript
Peptides. Author manuscript; available in PMC 2020 April 16.

de Almeida et al.

Page 25

Author Manuscript

Fig. 4.

PI uptake of AMPs. S aureus JE 2 (A) and E. coli K12 (B) cells (1 × 107 CFU) were
untreated, treated with AMPs (2xMIC) or treated with Polymixyn B (PMB, 16 μg/mL) for
120 min. The PI fluorescence intensity was then measured at 20 min intervals for a total of
120 min. PMB is known to kill Gram-negative bacteria by disrupting cell membrane and
was used as a positive control.
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Fig. 5.

Stability of Cit 1.1 and the AMP Analogues in Human Serum studied by LC-MS. AMP
serum concentrations are normalized to initial concentrations (0 min, 100% AMP). The data
is plotted as mean ± SD from triplicate measurements.
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Fig. 6.

Summary of the Cit 1.1 SAR.
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Antimicrobial activities of Cit 1.1 (AMP-001) and AMP analogs.
Minimal inhibitory concentration (MIC) μg/mL

Author Manuscript
Author Manuscript

a

a

b

c

Peptide sequence

Peptide code

GLFDVIKKVASVIGGL

AMP-001/Cit 1.1

32

32

−3.60

SarLFDVIKKVASVIGGL

AMP-002

32

64

−3.17

AcGLFDVIKKVASVIGGL

AMP-003

≥256

≥256

−3.78

(CH3)3GLFDVIKKVASVIGGL

AMP-004

≥256

≥256

−6.14

Hydrazine-LFDVIKKVASVIGGL

AMP-005

≥256

≥256

−2.50

GLFDVI(Orn)(Orn)VASVIGGL

AMP-006

d

32

−4.49

GLFDVI(Dab)(Dab)VASVIGGL

AMP-007

> 32

32

−5.52

GLFDVI(Dpr)(Dpr)VASVIGGL

AMP-008

> 32

64

−5.64

GLFDVI(Cit)KVASVIGGL

AMP-009

128

256

−4.56

(CH3)3GLFDVIK(CH3)3K(CH3)3VASVIGGL

AMP-010

≥256

≥256

−13.64

GLFDVIK(CH3)3K(CH3)3VASVIGGL

AMP-011

≥256

≥256

−10.29

GLFDVIRRVASVIGGL

AMP-012

16

32

−5.16

GLFDVIRKVASVIGGL

AMP-013

16

> 32

−4.38

GLFDVIKKGVASVIGGL

AMP-014

≥256

64

−4.71

GLFEVIKKVASVIGGL

AMP-015

> 32

−3.31

GLWDVIKKVASVIGGL

AMP-016

8

16

−3.50

GLWRVIRKVASVIGGL

AMP-017

16

32

−4.55

PhenylGlyLWDVIRKVASVIGGL

AMP-018

16

> 32

−2.34

GL(Biphenylalanine)DVIKKVASVIGGL

AMP-019

8

32

−1.85

GL(1-Nap)DVIKKVASVIGGL

AMP-020

8

64

−2.61

SarLWDVIRKVASVIGGL

AMP-021

Ne

Ne

−3.85

Sa

Ec

> 32

d

> 32

LogP

Staphylococcus aureus JE2 MRSA.

b

Escherichia coli K12.

c

Calculated from MarvinSketch Version 14.9.

d

64.
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Author Manuscript
AMP-001/Cit 1.1
AMP-006
AMP-012
AMP-013
AMP-015
AMP-016
AMP-017
AMP-018
AMP-019
AMP-020
AMP-021

GLFDVIKKVASVIGGL

GLFDVI(Orn)(Orn)VASVIGGL

GLFDVIRRVASVIGGL

GLFDVIRKVASVIGGL

GLFEVIKKVASVIGGL

GLWDVIKKVASVIGGL

GLWRVIRKVASVIGGL

PhenylGlyLWDVIRKVASVIGGL

GL(Biphenylalanine)DVIKKVASVIGGL

GL(1-Nap)DVIKKVASVIGGL

SarLWDVIRKVASVIGGL

Peptides. Author manuscript; available in PMC 2020 April 16.

Cryptococcus neoformans var. grubii H99 ATCC 20882.

g

Candida albicans ATCC 90028.

f

Klebsiella pneumoniae ATCC 700603.

Acinetobacter baumannii ATCC 19606.

e

d

c
Psedomonas aeruginosa ATCC 27853.

Escherichia coli ATCC 25922.

b

Staphylococcus aureus ATCC 43300 MRSA.

a

Peptide code

Peptide sequence

Minimal inhibitory concentration (MIC) μg/mL

8

4

4

8

4

4

32

16

16

32

32

a

Sa

16

32

32

> 32

4

> 32

> 32

> 32

32

> 32

> 32

b

Ec

> 32

> 32

> 32

> 32

> 32

> 32

> 32

> 32

> 32

> 32

> 32

c

Pa

32

> 32

> 32

> 32

8

> 32

> 32

> 32

> 32

> 32

> 32

d

Kp

4

16

16

32

2

16

> 32

32

32

> 32

32

e
Ab

32

32

32

32

32

32

> 32

> 32

16

> 32

> 32

f

Ca

16

> 32

> 32

8

2

8

16

16

16

32

16

g
Cn
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Additional antimicrobial activities of Cit 1.1 (AMP-001) and selected AMP analogs.
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Table 3
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AMP cytotoxicity and hemolytic activity.
IC50 (μg/mL)
a

HC50 (μg/mL)

Author Manuscript

Peptide sequence

Peptide code

GLFDVIKKVASVIGGL

AMP-001/Cit 1.1

20.98

> 32

GLFDVI(Orn)(Orn)VASVIGGL

AMP-006

> 32

> 32

GLFDVIRRVASVIGGL

AMP-012

17.64

18.2

GLFDVIRKVASVIGGL

AMP-013

21.26

> 32

GLFEVIKKVASVIGGL

AMP-015

> 32

> 32

GLWDVIKKVASVIGGL

AMP-016

> 32

16.85

GLWRVIRKVASVIGGL

AMP-017

18.10

26.7

PhenylGlyLWDVIRKVASVIGGL

AMP-018

19.44

> 32

GL(Biphenylalanine)DVIKKVASVIGGL

AMP-019

17.04

> 32

GL(1-Nap)DVIKKVASVIGGL

AMP-020

16.85

> 32

SarLWDVIRKVASVIGGL

AMP-021

30.90

> 32

HEK-293

Human red blood cells

a

Human embryonic kidney cells (ATCC CRL-1573). Assays were performed by The Community for Antimicrobial Drug Discovery (CO-ADD),
Australia.
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